The effect of various concentrations of Aegle marmelos (AME) on the doxorubicin (DOX)-induced genotoxic effects in mice bone marrow was studied. Treatment of mice with different concentrations of DOX resulted in a dose-dependent elevation in the frequency of micronucleated polychromatic (MPCE) as well as normochromatic (MNCE) erythrocytes in mouse bone marrow. The frequencies of MPCE and MNCE increased with scoring time, and the greatest elevation for MPCE was observed at 48 hours post-DOX treatment, whereas a maximum increase in MNCE was observed at 72 hours post-DOX treatment. This increase in MPCE and MNCE was accompanied by a decline in the polychromatic erythrocytes–normochromatic erythrocytes (PCE/NCE) ratio, which showed a DOX-dose-dependent decline. Treatment of mice with 200, 250, 300, 350, and 400 mg/kg body weight of AME, orally once daily for 5 consecutive days before DOX treatment, significantly reduced the frequency of DOX-induced micronuclei accompanied by a significant elevation in the PCE/NCE ratio at all scoring times. The greatest protection against DOX-induced genotoxicity was observed at 350 mg/kg AME. The protection against DOX-induced genotoxicity by AME may be due to inhibition of free radicals and increased antioxidant status.
Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health Syst Pharmacol. 1996; 53:2713-2723.
2.
Gentile JM, Rahimi S, Zwiesler J, Gentile GJ, Ferguson LR. Effect of selected antimutagens on the genotoxicity of antitumor agents. Mutat Res. 1998;402:289-298.
3.
Sobti RC, Krishan A, Davies J. Cytokinetic and cytogenetic effect of agricultural chemicals on human lymphoid cells in vitro. II. Organochlorine pesticides. Arch Toxicol. 1983;52: 221-231.
4.
Delmanto RD, de Lima PL, Sugui MM, et al. Antimutagenic effect of Agaricus blazei Murrill mushroom on the genotoxicity induced by cyclophosphamide. Mutat Res. 2001;496:15-21.
5.
De Lima PL, Delmanto RD, Sugui MM, et al. Lentinula edodes (Berk.) Pegler (Shiitake) modulates genotoxic and mutagenic effects induced by alkylating agents in vivo. Mutat Res. 2001;496:23-32.
6.
Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med. 1981;305:139-153.
7.
Hitchcock-Bryan S, Gelber RD, Cassady JR, Sallan SE. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986;14:211-215.
8.
Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol. 1998;25:10-14.
9.
Weiss RB. Toxicity of chemotherapy: the last decade. Semin Oncol. 2006;33:1-1.
10.
Zweier JL., Reduction of O2 by iron-adriamycin. J Biol Chem. 1984;259:6056-6058.
11.
Bean CL, Armstrong MJ, Galloway SM. Effect of sampling time on chromosome aberration yield for 7 chemicals in Chinese hamster ovary cells. Mutat Res. 1992;265:31-44.
12.
Al-Harbi MM. Effect of captopril on the cytological and biochemical changes induced by adriamycin. Food Chem Toxicol. 1993;31:209-212.
13.
Al-Shabanah OA. Inhibition of adriamycin-induced micronuclei by desferrioxamine in Swiss albino mice. Mutat Res. 1993;301:107-111.
14.
Delvaeye M, Verovski V, De Neve W, Storme G. DNA breakage, cytotoxicity, drug accumulation and retention in two human ovarian tumor cell lines AZ224 and AZ364 treated with adriamycin, modulated by verapamil. Anticancer Res. 1993;13:1533-1538.
15.
Jagetia GC, Nayak V. Micronuclei-induction and its correlation to cell survival in HeLa cells treated with different doses of adriamycin. Cancer Lett. 1996;110:123-128.
16.
Jagetia GC, Nayak V. Effect of doxorubicin on cell survival and micronuclei formation in HeLa cells exposed to different doses of gamma-radiation. Strahlenther Onkol. 2000;176: 422-428.
17.
Jagetia GC, Aruna R. Correlation between cell survival and micronuclei-induction in HeLa cells treated with adriamycin after exposure to various doses of gamma-radiation. Toxicol Lett. 2000;115:183-193.
18.
Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
19.
Dhawan A, Kayani MA, Parry JM, Parry E, Anderson D. Aneugenic and clastogenic effects of doxorubicin in human lymphocytes. Mutagenesis. 2003;18:487-490.
20.
Buckton KE. Chromosome aberrations in patients treated with x-ray irradiation for ankylosing spondylitis. In: Ishihara T, Sasaki M, eds. Radiation-Induced Chromosome Damage in Man. New York, NY: Alan Liss; 1983:491-511.
21.
Savage JRK. Annotation: classification and relationships of induced chromosomal structural changes. J Med Genet. 1976;13:103-122.
22.
Heddle JA. A rapid in vivo test for chromosomal damage. Mutat Res. 1973;61:187-190.
23.
Heddle JA, Carrano AV. The DNA content of micronuclei induced in mouse bone marrow by γ-irradiation: evidence that micronuclei arises from acentric chromosomal fragments. Mutat Res. 1977;44:63-69.
24.
Yamamoto KI, Kikuchi Y. A comparison of diameters of micronuclei induced by clastogens and poisons. Mutat Res. 1980;71:127-131.
25.
Heddle JA, Raj AS, Krepinsky AB. The micronucleus assay. Part II. In vitro. In: Stich HF, San KHC, eds. Short-term Tests for Chemical Carcinogens. New York, NY: Springer; 1981:250-254.
26.
Heddle JA, Hite M, Kirkhart K, et al. The induction of micronuclei as a measure of genotoxicity, a report of the US Environmental Protection Agency Gene-Tox Program. Mutat Res. 1983;123:61-118.
27.
Almassy Z, Krepinsky AB, Bianco A, Koteles GJ. The present state and perspectives of micronucleus assay in radiation protection: a review. Int J Rad Appl Instrum. 1987;38:241-249.
28.
Schmid W. The micronucleus test. Mutat Res. 1975;31:9-12.
29.
Sharma RK, Dash B. Carka Samhita. Vol 2. Varanasi, India: Chowkamba Sanskrit Series Office; 1998.
30.
CHEMEXCIL. Selected medicinal plants of India. In: Pharmaceutical and Cosmetic Export Promotion Council. Basic Chemicals. Bombay, India: CHEMEXCIL; 1992:205-207.
31.
Shoba FG, Thomas M. Study of antidiarrhoeal activity of four medicinal plants in castor-oil induced diarrhoea. J Ethnopharmacol. 2001;76:73-76.
32.
Rastogi RM, Mehrotra BN. Compendium of Indian Medicinal Plants. Vol 1. Lucknow, India: Central Drug Research Institute; 1990.
33.
Haravey SK. A preliminary communication of the action of Aegle marmelos (bael) on heart. Indian J Med Res. 1968;56:327-331.
34.
Suffness M, Douros J. Drugs of plant origin. In: De Vita VT, ed. Methods in Cancer Research. Vol 16. New York, NY: Academic Press; 1979:73-94.
35.
Jagetia GC, Venkatesh P. Radioprotection by oral administration of Aegle marmelos (L.) Correa in vivo. J Environ Pathol Toxicol Oncol. 2005;24:315-332.
36.
Jagetia GC. Influence of chlorpromazine, bleomycin and WR-2721 singly or in combination on the formation of radiationinduced micronuclei in mice bone marrow. Strahlenther Onkol. 1994;170:648-653.
37.
Canellos GP, Arseneau JC, DeVita VT, Whang-Peng J, Johnson RE. Second malignancies complicating Hodgkin's disease in remission. Lancet. 1975;1:947-949.
38.
Casciato DA, Scott JL. Acute leukemia following prolonged cytotoxic agent therapy. Medicine (Baltimore). 1979;58:32-47.
39.
Ferguson LR, Pearson AE. The clinical use of mutagenic anticancer drugs. Mutat Res. 1996;355:1-12.
40.
Hospers GA, Eisenhauer EA, de Vries EG. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents: a review, indications for use and prospects. Br J Cancer. 1999;80:629-638.
41.
Van Acker SA, Kramer K, Grimbergen JA, et al. Monohydroxyethylrutoside as protector against chronic doxorubicininduced cardiotoxicity. Br J Pharmacol. 1995;115: 1260-1264.
42.
Van Acker FAA, Van Acker SABE, Kramer K, Haenen GRMM, Bast A, Van der Vijgh WJF. 7-Monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res. 2000;6: 1337-1341.
43.
Vidhya N, Devraj SN. Antioxidant effect of eugenol in rat intestine. Ind J Exp Biol. 1999;37:1192-1195.
44.
Holm C, Goto T, Wang JC, Botstein D. DNA topoisomerase II is required at the time of mitosis in yeast. Cell. 1985;41: 553-563.
45.
Uemura T, Yanagida M. Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis. EMBO J. 1986;5:1003-1010.
46.
Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell. 1987;50:917-925.
47.
Yanagida M, Sternglanz R. Genetics of DNA topoisomerases. In: Cozzarelli NR, Wang JC, eds. DNA Topology and Its Biological Effects. Cold Spring Harbor, NY: Cold Spring Harbor Lab Press; 1990:299-320.
48.
Liu LF, Liu CC, Alberts BM. Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break. Cell. 1980;19:697-707.
49.
Anderson RD, Berger NA. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents. Mutat Res. 1994;309:109-142.
50.
Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989;49:5870-5878.
51.
Del Bino G, Skierski JS, Darzynkiewicz Z. The concentrationdependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells. Exp Cell Res. 1991;195:485-491.
52.
Trevino AV, Woynarowska BA, Herman TS, Priebe W, Woynarowski JM. Enhanced topoisomerase II targeting by annamycin and related 4-demethoxy anthracycline analogues. Mol Cancer Ther. 2004;3:1403-1410.
53.
Natarajan AT, Darroudi F, Mullenders LH, Meijers M. The nature and repair of DNA lesions that lead to chromosomal aberrations induced by ionizing radiations. Mutat Res. 1986;160:231-236.
54.
Boucher R, Livingston GK, Que Hee SS. In vitro micronucleus bioassay of human peripheral lymphocytes for adriamycin in the presence of cyclophosphamide and urines of patients administered anticancer drugs. Environ Mol Mutagen. 1993;21:372-382.
55.
Jagetia GC, Venkatesh P, Baliga MS. Evaluation of the radioprotective effect of Aegle marmelos (L.) Correa in cultured human peripheral blood lymphocytes exposed to different doses of gamma-radiation: a micronucleus study. Mutagenesis. 2003;18:387-393.
56.
Jagetia GC, Venkatesh P. Inhibition of radiation-induced clastogenicity by Aegle marmelos (L.) Correa in mice bone marrow exposed to different doses of γ-radiation. Hum Exp Toxicol. In press.
57.
Lu HZ, Geng BQ, Zhu YL, Yong DG. Effects of beta-carotene on doxorubicin-induced cardiotoxicity in rats. Zhongguo Yao Li Xue Bao. 1996;17:317-320.
58.
Gulkac MD, Akpinar G, Ustun H, Ozon Kanli A. Effects of vitamin A on doxorubicin-induced chromosomal aberrations in bone marrow cells of rats. Mutagenesis. 2004;19:231-236.
59.
Costa WF, Nepomuceno JC. Protective effects of a mixture of antioxidant vitamins and minerals on the genotoxicity of doxorubicin in somatic cells of Drosophila melanogaster. Environ Mol Mutagen. 2006;47:18-24.
60.
D'Agostini F, Bagnasco M, Giunciuglio D, Albini A, De Flora S. Inhibition by oral N-acetylcysteine of doxorubicin-induced clastogenicity and alopecia, and prevention of primary tumors and lung micrometastases in mice. Int J Oncol. 1998;3:217-224.
61.
Al-Gharably NM. Effect of probucol on the cytological and biochemical changes induced by adriamycin in Swiss albino mice. Res Commun Mol Pathol Pharmacol. 1996;94:289-303.
62.
Bardeleben RV, Dunkern T, Kaina B, Fritz G. The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int J Mol Med. 2002; 10:473-479.
63.
Sadzuka Y, Sugiyama T, Shimoi K, Kinae N, Hirota S. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett. 1997;92:1-7.
64.
Jagetia GC, Aruna R. Teniposide (VM-26) treatment enhances the radiation-induced micronuclei in the bone marrow of mouse. Mutat Res. 1999;425:87-98.
65.
Slavotinek A, Perry PE, Sumner AT. Micronuclei in neonatal lymphocytes treated with the topoisomerase II inhibitors amsacrine and etoposide. Mutat Res. 1993;319:215-222.
66.
Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727-741.
67.
Painter RB. Inhibition of DNA replicon initiation by 4-nitroquinoline 1-oxide, adriamycin, and ethyleneimine. Cancer Res. 1978;38:4445-4449.
68.
Kiyomiya K, Matsuo S, Kurebe M. Differences in intracellular sites of action of adriamycin in neoplastic and normal differentiated cells. Cancer Chemother Pharmacol. 2001;47:51-56.
69.
Pommier Y, Schwartz RE, Zwelling LA, Kohn KW. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry. 1985;24:6406-6410.
70.
Guano F, Pourquier P, Tinelli S, et al. Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol. 1999;56:77-84.
71.
Bachur NR, Gordon SL, Gee MV, Kon H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A. 1979;76:954-957.
72.
Eliot H, Gianni L, Myers C. Oxidative destruction of DNA by the adriamycin-iron complex. Biochemistry. 1984;23:928-936.
73.
Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys. 1999;368:421-428.
74.
Powis G. Free radical formation by antitumor quinones. Free Radical Biol Med. 1989;6:63-101.
75.
Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990;4:3076-3086.
76.
Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 2nd ed.New York, NY: Oxford University Press; 1989:543-543.
77.
Doroshow JH. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem Biophys Res Commun. 1986;135:330-335.
78.
Doroshow JH. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc Natl Acad Sci U S A. 1986;83:4514-4518.
79.
Monti E, Cova D, Guido E, Morelli R, Oliva C. Protective effect of the nitroxide tempol against the cardiotoxicity of adriamycin. Free Radic Biol Med. 1996;21:463-470.
80.
Korina LG, Afana'ev IB. Antioxidant and chelating properties of flavonoids. Adv Pharmacol. 1997;38:151-163.
81.
Rompelberg CJ, Stenhuis WH, de Vogel N, van Osenbruggen WA, Schouten A, Verhagen H. Antimutagenicity of eugenol in the rodent bone marrow micronucleus test. Mutat Res. 1995;346:69-75.
82.
Vijayalaxmi KK, Venu R. In vivo anticlastogenic effects of L-ascorbic acid in mice. Mutat Res. 1999;438:47-51.
83.
Duthie GG, Duthie SJ, Kyle JAM. Plant-polyphenol in cancer and heart disease: implication as nutritional antioxidant. Nutr Res Rev. 2000;13:79-79.
84.
Jagetia GC, Venkatesh P, Baliga MS. Evaluation of the radioprotective effect of bael leaf (Aegle marmelos) extract in mice. Int J Radiat Biol. 2004;80:281-290.
85.
Singh RP, Banerjee S, Rao AR. Effect of Aegle marmelos on biotransformation enzyme systems and protection against freeradical-mediated damage in mice. J Pharm Pharmacol. 2000;52:991-1000.
86.
Sabu MC, Kuttan R. Antidiabetic activity of Aegle marmelos and its relationship with its antioxidant properties. Indian J Physiol Pharmacol. 2004;48:81-88.
87.
Kleiner HE, Vulimiri SV, Miller L, Johnson WH Jr, Whitman CP, DiGiovanni J. Oral administration of naturally occurring coumarins leads to altered phase I and II enzyme activities and reduced DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of SENCAR mice. Carcinogenesis. 2001;22:73-82.
88.
Mackenzie D. Swallow it whole. New Sci. 2001;2292:39-39.
89.
Jagetia GC, Venkatesh P, Baliga MS. Aegle marmelos (L.) Correa inhibits the proliferation of transplanted Ehrlich ascites carcinoma in mice. Biol and Pharm Bull. 2005;28:58-64.
